Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-06-21T21:37:58.806Z Has data issue: false hasContentIssue false

34 - Pharmacogenomics: clinical applications

Published online by Cambridge University Press:  17 August 2009

By
Gillian Smith ,
Mark Chamberlain  and
C. Roland Wolf
Edited by
Alan Wright  and
Nicholas Hastie
Alan Wright
Affiliation:
MRC Human Genetics Unit, Edinburgh
Nicholas Hastie
Affiliation:
MRC Human Genetics Unit, Edinburgh
Get access

Summary

Introduction

There is now a large body of evidence indicating that genetic factors can influence treatment response in a variety of human diseases. Pharmacogenetics, defined as the study of the genetic basis for individuality in response to drugs (Vogel, 1959) or use of genetic analysis to predict drug response, efficacy and toxicity (Roses, 2004) has seen an almost exponential rise in peer-reviewed publications in the last 10 years (Figure 34.1). The closely related field of pharmacogenomics can be defined as the use of genetic approaches in drug discovery and use and encompasses the study of all genes which may influence drug response although, as illustrated in Figure 34.1, the terms pharmacogenetics and pharmacogenomics are often used interchangeably.

Inter-individual differences in response to commonly prescribed drugs are increasingly recognized. Serious adverse drug reactions (ADRs) have been estimated to occur in more than 2 million patients/year in the USA and result in more than 100 000 fatalities; meta-analysis of a number of US-based prospective studies suggest that ADRs are the fourth leading cause of death, after heart disease, cancer and stroke (Lazarou et al., 1998). A recent UK-based prospective study reported that up to 6.5% of all hospital admissions in the UK are related to adverse drug reactions, with a projected annual cost to the National Health Service of £466 million (Pirmohamed et al., 2004).

Individuality in drug response can be both genetically and environmentally determined.

Type
Chapter
Information
Genes and Common Diseases
Genetics in Modern Medicine
 , pp. 516 - 528
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agundez, J. A., Martinez, C., Ledesma, M. C.et al. (1994). Genetic basis for differences in debrisoquine polymorphism between a Spanish and other white populations. Clin Pharmacol Ther, 55, 412–17.CrossRefGoogle ScholarPubMed
Aklillu, E., Herrlin, K., Gustafsson, L. L., Bertilsson, L. and Ingelman-Sundberg, M. (2002). Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics, 12, 375–83.CrossRefGoogle ScholarPubMed
Armstrong, V. W., Shipkova, M., Ahsen, N. and Oellerich, M. (2004). Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit, 26, 220–6.CrossRefGoogle ScholarPubMed
Bell, R., Verma, S., Untch, M., Cameron, D. and Smith, I. (2004). Maximizing clinical benefit with trastuzumab. Semin Oncol, 31, 35–44.CrossRefGoogle ScholarPubMed
Bertilsson, L., Dahl, M. L., Sjoqvist, F.et al. (1993). Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet, 341, 63.CrossRefGoogle ScholarPubMed
Blaisdell, J., Jorge-Nebert, L. F., Coulter, S.et al. (2004). Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics, 14, 527–37.CrossRefGoogle ScholarPubMed
Blum, M., Demierre, A., Grant, D. M., Heim, M. and Meyer, U. A. (1991). Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA, 88, 5237–41.CrossRefGoogle ScholarPubMed
Breckenridge, A., Lindpaintner, K., Lipton, P.et al. (2004). Pharmacogenetics: ethical problems and solutions. Nat Rev Genet, 5, 676–80.CrossRefGoogle ScholarPubMed
Daly, A. K. and Aithal, G. P. (2003). Genetic regulation of warfarin metabolism and response. Semin Vasc Med, 3, 231–8.Google Scholar
Engman, H. A., Lennernas, H., Taipalensuu, J.et al. (2001). CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies. J Pharm Sci, 90, 1736–51.CrossRefGoogle ScholarPubMed
Evans, W. E. (2004). Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit, 26, 186–91.CrossRefGoogle ScholarPubMed
Forrester, L. M., Henderson, C. J., Glancey, M. J.et al. (1992). Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J, 281, 359–68.CrossRefGoogle Scholar
Fukuoka, M., Yano, S., Giaccone, G.et al. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 21, 2237–46.CrossRefGoogle ScholarPubMed
Garcia-Martin, E., Martinez, C., Tabares, B., Frias, J. and Agundez, J. A. (2004). Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther, 76, 119–27.CrossRefGoogle ScholarPubMed
Goldstein, J. A. (2002). CYP2C9 polymorphisms and CYP2C9*2 genotyping primers. Br J Clin Pharmacol, 53, 409–10.CrossRefGoogle ScholarPubMed
Gonzalez, F. J., Skoda, R. C., Kimura, S.et al. (1988). Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 331, 442–6.CrossRefGoogle ScholarPubMed
Gough, A. C., Miles, J. S., Spurr, N. K.et al. (1990). Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature, 347, 773–6.CrossRefGoogle ScholarPubMed
Guengerich, F. P. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol, 39, 1–17.CrossRefGoogle ScholarPubMed
Hustert, E., Zibat, A., Presecan-Siedel, E.et al. (2001). Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos, 29, 1454–9.Google ScholarPubMed
Ingelman-Sundberg, M. (2004). Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci, 25, 193–200.CrossRefGoogle ScholarPubMed
Ingelman-Sundberg, M., Oscarson, M. and McLellan, R. A. (1999). Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci, 20, 342–9.CrossRefGoogle ScholarPubMed
Johansson, I., Lundqvist, E., Bertilsson, L.et al. (1993). Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA, 90, 11825–9.CrossRefGoogle ScholarPubMed
Johansson, I., Oscarson, M., Yue, Q. Y.et al. (1994). Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol, 46, 452–9.Google ScholarPubMed
Kim, K., Johnson, J. A. and Derendorf, H. (2004). Differences in drug pharmacokinetics between East asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol, 44, 1083–105.CrossRefGoogle ScholarPubMed
Kirchheiner, J., Brosen, K., Dahl, M. L.et al. (2001). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Acta Psychiatr Scand, 104, 173–92.CrossRefGoogle Scholar
Kirchheiner, J., Nickchen, K., Bauer, M.et al. (2004). CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Mol Psychiatry, 9, 442–73.CrossRefGoogle Scholar
Koch, I., Weil, R., Wolbold, R., Brockmoller, J.et al. (2002). Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos, 30, 1108–14.CrossRefGoogle ScholarPubMed
Kuehl, P., Zhang, J., Lin, Y.et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 27, 383–91.CrossRefGoogle ScholarPubMed
Lazarou, J., Pomeranz, B. H. and Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama, 279, 1200–5.CrossRefGoogle ScholarPubMed
Lerer, B. and Macciardi, F. (2002). Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol, 5, 255–75.CrossRefGoogle ScholarPubMed
Lesko, L. J. and Woodcock, J. (2002). Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J, 2, 20–4.CrossRefGoogle ScholarPubMed
Lou, Y. C., Ying, L., Bertilsson, L. and Sjoqvist, F. (1987). Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet, 2, 852–3.Google Scholar
Marsh, S. and McLeod, H. L. (2004). Pharmacogenetics of irinotecan toxicity. Pharmacogenomics, 5, 835–43.CrossRefGoogle ScholarPubMed
Matsumura, K., Saito, T., Takahashi, Y.et al. (2004). Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol Pharmacol, 65, 326–34.CrossRefGoogle ScholarPubMed
Nicholson, J. K. and Wilson, I. D. (2003). Opinion: understanding ‘global’ systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov, 2, 668–76.CrossRefGoogle Scholar
Paez, J. G., Janne, P. A., Lee, J. C.et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497–500.CrossRefGoogle ScholarPubMed
Pao, W., Miller, V., Zakowski, M.et al. (2004). EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 101, 13306–11.CrossRefGoogle ScholarPubMed
Patel, J. and Mitra, A. K. (2001). Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics, 2, 401–15.CrossRefGoogle ScholarPubMed
Pirmohamed, M., James, S., Meakin, S.et al. (2004). Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Bmj, 329, 15–19.CrossRefGoogle ScholarPubMed
Raucy, J. L. (2003). Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos, 31, 533–9.CrossRefGoogle ScholarPubMed
Roses, A. D. (2004). Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet, 5, 645–56.CrossRefGoogle ScholarPubMed
Sachse, C., Brockmoller, J., Bauer, S. and Roots, I. (1997). Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet, 60, 284–95.Google Scholar
Sackeim, H. A. (2001). The definition and meaning of treatment-resistant depression. J Clin Psychiatry, 62 Suppl 16, 10–17.Google ScholarPubMed
Schuetz, J. D., Beach, D. L. and Guzelian, P. S. (1994). Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics, 4, 11–20.CrossRefGoogle ScholarPubMed
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther, 270, 414–23.Google ScholarPubMed
Smith, G., Carey, F. A., Beattie, J.et al. (2002). Mutations in APC, Kirsten-ras, and p53–alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA, 99, 9433–8.CrossRefGoogle ScholarPubMed
Solus, J. F., Arietta, B. J., Harris, J. R.et al. (2004). Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics, 5, 895–931.CrossRefGoogle Scholar
Spurr, N. K., Gough, A. C., Stevenson, K. and Wolf, C. R. (1989). The human cytochrome P450 CYP3 locus: assignment to chromosome 7q22-qter. Hum Genet, 81, 171–4.CrossRefGoogle ScholarPubMed
Stoehlmacher, J., Park, D. J., Zhang, W.et al. (2002). Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst, 94, 936–42.CrossRefGoogle ScholarPubMed
Stoehlmacher, J., Park, D. J., Zhang, W.et al. (2004). A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer, 91, 344–54.CrossRefGoogle ScholarPubMed
Stubbins, M. J., Harries, L. W., Smith, G., Tarbit, M. H. and Wolf, C. R. (1996). Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics, 6, 429–39.CrossRefGoogle ScholarPubMed
Vastag, B. (2004). Research unveils the ‘who’ and ‘why’ of gefitinib. J Natl Cancer Inst, 96, 1352–4.CrossRefGoogle ScholarPubMed
Vogel, F. (1959). Moderne Problem der Humangenetik. Ergib Inn Kinderheild, 12, 52–125.Google Scholar
Wakeling, A. E., Guy, S. P., Woodburn, J. R.et al. (2002). ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res, 62, 5749–54.Google ScholarPubMed
Woodahl, E. L. and Ho, R. J. (2004). The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab, 5, 11–19.CrossRefGoogle ScholarPubMed
Zhang, J., Kuehl, P., Green, E. D.et al. (2001). The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics, 11, 555–72.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×